Kevin Harrington, PhD on KEYNOTE-048 #ASCO2020 #ASCO

Kevin Harrington, PhD on KEYNOTE-048 #ASCO2020 #ASCO

User Photo
Cancer-News

4 weeks
53 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression after the next line of therapy following pembrolizumab or P plus chemotherapy vs EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma.

Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6505

Up Next Autoplay
User Photo